ArticleCancer management and research2025
Association of PD-L1 Expression with Lymph Node Metastasis and Clinical Stage in Ampulla of Vater Cancer: An Observational Study.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Compartment-Specific CD8 Infiltration and Disease-Specific Survival in Resected Ampullary Adenocarcinoma.Cancer research communications · 2026Article
- Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreatic cancer: a retrospective analysis.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ampulla of Vater cancer is a subtype of periampullary cancer originating from pancreatic ducts and the bile ducts. Immune checkpoint proteins, particularly Programmed Death-Ligand 1 (PD-L1), show a crucial function in influencing cancer progression, tumor microenvironment, and immune evasion. This study investigates the association between PD-L1 expression and clinical characteristics in patients with ampulla of Vater cancer. Methods: A retrospective observational study was carried out at a general hospital in West Java, Indonesia, from July 2019 to June 2024. Forty-four patients diagnosed with ampulla of Vater cancer were included. PD-L1 expression was evaluated using immunohistochemistry, and clinicopathological data were analyzed using chi-square, Mann-Whitney, and independent Results: There were 44 research subject. The PD-L1 expression was positive in 59.1% of patients and negatively associated with carcinoembryonic antigen (CEA) levels (p = 0.010). There was a significant association between PD-L1 positivity and lymph node involvement (p = 0.042) and clinical stage (p = 0.017). No significant association was found between PD-L1 expression and age, sex, histopathological grade, or distant metastasis. Conclusion: PD-L1 expression in ampulla of Vater cancer is significantly associated with higher lymph node metastasis and advanced clinical stage but not with age, sex, or tumor differentiation. These findings suggest PD-L1 as a potential prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.